SBIR/STTR Research Award
WHOLE ANIMAL ASSAY FOR ANGIOGENESIS INHIBITION
Award amount
$0Program and phase
SBIR · Phase IAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHYLONIX PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Currently there is strong interest in
natural proteins, such as thrombospondins, Platelet factor-4, angiostatin and
endostatin, as therapeutics for cancer and other diseases, because of the lack
of side effects and drug resistance development. Phase I studies demonstrated
that the zebrafish is a viable whole animal model for screening proteins and
chemical compounds for anti-angiogenic effects. An enzyme assay was
successfully developed to quantify vessel growth and a clear dose response was
observed for several drugs. In Phase II research, the enzyme assay will be used
to determine optimum assay conditions for protein drug testing, and then used
to screen therapeutic drug candidates. Since comprehensive commercial drug
screening programs rely on a number of confirmatory assays to assess drug
specificity, Phase II research will also develop a family of vessel specific
monoclonal antibody (mAb) based assays to complement the enzyme assay. Phase II
research will also use the vessel specific mAb based markers to elucidate the
mechanisms of angiogenesis.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
Technology keywords
Not reported